Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Dynal to provide component for Xcyte Therapies' activated T-cell product

Dec. 22, 1999

Sumitomo applies for approval of amrubicin

Dec. 22, 1999

AstraZeneca commences phase II monotherapy trials of ZD-0473

Dec. 21, 1999

Discovery of potent FTase inhibitors with excellent cellular and in vivo activity reported by Abbott

Dec. 21, 1999

Oxford Asymmetry achieves first milestone in collaboration with Ontogeny

Dec. 21, 1999

Phase I clinical trial initiated with OSI's second anticancer agent

Dec. 20, 1999

Genentech's rhuMAb-VEGF will move to phase III study

Dec. 20, 1999

ImClone Systems files IND in U.S. for antiangiogenic agent

Dec. 20, 1999

BMS and Oxigene establish agreement for combretastatin antitumor agents

Dec. 17, 1999

Targeted Genetics commences phase I trial of tgDCC-E1A for ovarian cancer

Dec. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...